Prior to this study, cilostazol, an antithrombotic drug, was thought to exist as a single
crystalline phase with a melting point of∼ 159° C (Form A). On cooling, melts often form a …

Cilostazol is practically insoluble in water and thus results in poor bioavailability. Only a few
approaches have been reported for improving the bioavailability of cilostazol. Solid …

The physico-chemical properties of cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,
4-dihydro-2 (1H)-qui nolinone, OPC-13013), a new potential antithrombotic and vasodilating …

The cocrystal formation of pharmaceuticals can improve the various physical properties of
drugs, such as solubility, without the need for chemical modification of the drug substances …

The objectives of this study are to enhance the oral bioavailability of cilostazol (CLZ), which
is a poorly soluble compound, by cocrystallization and to evaluate the correlation between …

The purpose of the present study was to investigate oral bioavailability of an immediate
release tablet containing wet-milled crystals of a poorly water-soluble drug, cilostazol, and to …

The therapeutic usage of cilostazol is limited owing to its poor aqueous solubility and oral
bioavailability. Our aim was to produce cilostazol crystals with small average particle size; …

This dissertation focuses on understanding the role of molecular recognition, kinetic, and
thermodynamic events in forming solid-state supramolecular assemblies. Poorly water …

A growing number of poorly water-soluble drug have been discovered, but the poor
bioavailability is a critical problem. In this study, physical properties and dissolution profiles …

Improvement in dissolution of the drugs having poor solubility is a challenge in
pharmaceutical industry. Micronization is one technique, employed for dissolution …